JP7707530B2 - Antiviral adhesive sheet - Google Patents

Description

This disclosure relates to an antiviral adhesive sheet.

From the viewpoint of hygiene, attempts have been made to impart antiviral properties to the surfaces of objects that people touch, such as interior materials such as walls, floors, and ceilings of buildings, furniture such as desks, fittings such as doors, interior materials of vehicles, office automation equipment, and touch panels.
Patent Document 1 discloses that an antiviral property is imparted to an object to which the antiviral property should be imparted by directly applying a composition containing a copper-based antiviral agent to the object.
Furthermore, Patent Document 2 discloses antiviral decorative sheets in which antiviral properties have been imparted to the surface in advance by forming a coating film of a composition containing a silver- or zinc-based antiviral agent on the surface of various decorative sheets used for the decorative surfaces of building interior materials, furniture, fittings, and the like, and such antiviral decorative sheets have also been adhered or laminated onto the object to which antiviral properties should be imparted or onto its substrate via an adhesive layer such as starch paste or two-component curing urethane resin.

Patent No. 6145758 Patent No. 6229429

However, as disclosed in Patent Document 1, direct application of an antiviral agent to an object to be imparted with antiviral properties, such as the interior of a building, or to its substrate requires a lot of work at the construction site, such as preparations such as masking (to prevent paint adhesion) of areas that do not need to be coated, application of the paint, drying, and cleanup, and takes a long time to complete, the finished appearance and antiviral performance vary depending on the skill of the painter (craftsman), and when the paint solvent is an organic solvent, measures such as health and hygiene and fire prevention are required. Furthermore, if the result of the coating work is poor, a failure, or a defect, redoing the coating work requires peeling and removing the paint, which is very time-consuming, expensive, and difficult.
In addition, as disclosed in Patent Document 2, in the case of adhesion or lamination of an antiviral decorative sheet to an object to be given antiviral properties or its substrate via an adhesive, the decorative sheet is manufactured under quality control at a factory, so there is an advantage that the antiviral performance is stable at a certain level. However, on the other hand, as in the case of direct coating, there is a lot of work at the construction site, such as preparation such as compounding and adjusting the adhesive, masking, coating the adhesive, waiting for adhesion, and cleaning up, and the construction time is long, and the finished appearance and adhesive performance over time vary depending on the skill of the adhesive construction contractor (craftsman), and when the adhesive solvent is an organic solvent, measures such as health and hygiene and fire prevention are required. In addition, if there is a defect, failure, or defect in the result of the adhesive lamination work, redoing the adhesive work again requires peeling and removing the adhesive decorative sheet, which is very laborious, costly, and time-consuming and difficult.
Furthermore, a common problem with both direct application of the antiviral agent and adhesion or lamination of the antiviral decorative sheet is that installation by amateurs (so-called "DIY" installation) can be difficult due to the complicated work at the installation site, the long working hours, and the high difficulty of redoing the installation.

The objective of the present disclosure is to provide a method for imparting antiviral properties to an object to be imparted with antiviral properties or its substrate that reduces the complexity of the work, shortens the work time, does not pose concerns about environmental hygiene or fire prevention due to organic solvents, and is easy to reapply.

To solve the above problems, the present disclosure provides an antiviral adhesive sheet that is formed by laminating an adhesive layer on one side of an antiviral agent-containing layer.

In the above antiviral adhesive sheet, the suction cup adhesive layer may be made of a one-component curing acrylic resin.

In the antiviral adhesive sheet, the coating amount of the suction cup adhesive layer may be 13 g/m ² or more and 70 g/m ² or less.

In the above-mentioned antiviral adhesive sheet, the suction cup adhesive layer has a plurality of concave shapes on both sides, and when the average value of the diameter of each opening of the concave shapes opening on one side is denoted as D ^ave ₁ and the average value of the diameter of each opening of the concave shapes opening on the other side of the suction cup adhesive layer is denoted as D ^ave ₂ ,
|D ^ave ₁ - ^{D ave} ₂ |/D ^ave ₂ ≦0.5
The above relationship may be satisfied.

According to the present disclosure, it is possible to provide a means for imparting antiviral properties to an object to be imparted with antiviral properties or to a substrate thereof, which reduces the complexity of the work, shortens the work time, does not pose concerns about environmental hygiene or fire prevention due to organic solvents, and is easy to reapply.

FIG. 1 is a cross-sectional view showing one embodiment of an antiviral adhesive sheet according to the present disclosure. FIG. 4 is a cross-sectional view showing another embodiment of the antiviral adhesive sheet of the present disclosure. FIG. 4 is a cross-sectional view showing another embodiment of the antiviral adhesive sheet of the present disclosure.

[Anti-viral adhesive sheet]
The antiviral adhesive sheet 100 of this embodiment comprises a layer containing an antiviral agent and a suction cup adhesive layer 50.
Hereinafter, the "layer containing an antiviral agent" may be referred to as the "antiviral agent-containing layer". There are also cases where the antiviral agent-containing layer is configured as a laminate in which other layers not containing an antiviral agent, such as a substrate, an adhesive layer, a decorative layer, etc., are further laminated on one (single) antiviral agent-containing layer (forms represented by FIGS. 2 and 3). Hereinafter, the part of the layer containing the antiviral agent in the antiviral agent-containing layer having such a laminate configuration is particularly referred to as the "single antiviral agent-containing layer" or "single antiviral agent-containing layer part", etc.
When the antiviral adhesive sheet 100 of the present embodiment simultaneously exhibits antibacterial and antifungal properties in addition to the antiviral properties, it can also be used as an antibacterial adhesive sheet and an antifungal adhesive sheet.

In general, even if an article is made of the same material and has the same layer structure, the correlation between the "antiviral," "antibacterial," and "antifungal" properties exhibited may or may not be effective depending on the type of virus, bacteria, or mold in question; the environmental conditions; the required level of antiviral, antibacterial, or antifungal properties; and the like. For this reason, the antiviral adhesive sheet of this embodiment may be applicable not only to antiviral uses but also to antibacterial uses depending on the type of bacteria, environmental conditions, and the required level of antibacterial properties. Note that since mold is a type of fungus, the antiviral adhesive sheet of this embodiment may also be applicable to antifungal uses depending on the type of mold, environmental conditions, and the required level of antifungal properties.

FIG. 1( a ) is a cross-sectional view showing a representative embodiment of an antiviral agent-containing layer 10 including a suction cup adhesive layer 50 constituting an antiviral adhesive sheet 100 of the present disclosure.
The antiviral adhesive sheet 100 in Figs. 1(a) to 1(c) is usually used with the XY plane facing directly towards a person.

The antiviral agent-containing layer 10 in Fig. 1(a) contains the antiviral agent 12 throughout the in-plane direction and thickness direction of the antiviral agent-containing layer 10. The antiviral agent-containing layer 10 in Fig. 1(b) contains the antiviral agent 12 near the surface side (upper side in the figure) of the antiviral agent-containing layer 10 in its in-plane directions (directions in the XY plane in the figure). The antiviral agent-containing layer 10 in Fig. 1(c) contains the antiviral agent 12 in a partial region in the in-plane direction on the surface side (upper side in the figure) of the antiviral agent-containing layer 10.
1(a) to 1(c), there are no particular limitations on the location where the antiviral agent 12 is present in the antiviral agent-containing layer 10. However, from the viewpoint of enhancing antiviral properties, it is preferable that the antiviral agent 12 be present in at least a partial region in the vicinity of the exposed surface of the antiviral agent-containing layer 10.

In this specification, the surface to which the antiviral agent-containing layer is exposed refers to the surface to which the planar direction of the antiviral agent-containing layer is exposed. The planar direction of the antiviral agent-containing layer is the XY direction in Figures 1 to 3.
In this specification, the vicinity of the surface where the antiviral agent-containing layer is exposed means the region within the range where the antiviral agent is contained in the thickness direction from the surface where the antiviral agent is exposed.
That is, when a radioactive compound (antiviral agent 6) described later is used as the antiviral agent 12, the antiviral agent 12 can be exhibited even in a form in which the antiviral agent 12 is absent on the surface of the antiviral agent-containing layer 10 and is present only inside the layer. However, in a form in which the antiviral agent 12 is used in other ways, the part of the antiviral agent-containing layer 10 in which the antiviral agent 12 is certainly exhibited is the part where the antiviral agent 12 is exposed to the outside from the antiviral agent-containing layer 10. Therefore, it is sufficient that at least one layer of the minimum unit consisting of the particles, atoms (including ionized ones), or molecules of the antiviral agent 12 is present on the surface of the antiviral agent-containing layer 10. For example, when the antiviral agent uses atoms or molecules as the minimum unit, it is sufficient to have a monoatomic layer or a monomolecular layer, and when the antiviral agent uses particles consisting of a plurality of atoms or molecules as the minimum unit, it is sufficient to have only a monoparticle layer.
However, in reality, when the antiviral agent 12 is formed in the antiviral-agent-containing layer 10 as a monoatomic layer, a monomolecular layer, or a monoparticle layer, in addition to the difficulty in terms of manufacturing technology, the antiviral agent 12 is easily detached or lost due to external forces such as friction, and the antiviral function is easily lost. In addition, some viruses may invade the inside of the antiviral-agent-containing layer 10 through gaps between the antiviral agent and the binder resin, etc.

Furthermore, the antiviral agent 12 may have the property of migrating (bleeding) over time from the inside of the antiviral agent-containing layer 10 toward the surface. In such a case, it is expected that the atoms, molecules, or particles of the antiviral agent 12 are configured in two or more layers on the surface of the antiviral agent-containing layer 10, or the antiviral agent 12 is distributed from the surface of the antiviral agent-containing layer 10 throughout the inside of the layer 10 and a part of the antiviral agent 12 is exposed from the surface of the antiviral agent-containing layer 10, and the antiviral agent 12 exposed on the surface layer of the layer 10 exhibits antiviral properties, and the antiviral agent that has fallen off or disappeared over time from the surface of the antiviral agent-containing layer 10 is complemented by the antiviral agent 12 that has migrated from the antiviral agent layer immediately below the antiviral agent layer laminated on the surface of the antiviral agent-containing layer 10 or from the inside of the antiviral agent-containing layer 10 being exposed from the surface of the antiviral agent-containing layer 10 or formed as a layer on the surface of the antiviral agent-containing layer 10.
Therefore, in reality, in many cases, atoms, molecules, or particles of the antiviral agent 12 are distributed and contained in the antiviral agent-containing layer 10 from the surface to a depth of a predetermined thickness, and a part of the antiviral agent 12 is exposed from the surface of the antiviral agent-containing layer 10 or forms a layer. Such a region in which atoms, etc. of the antiviral agent 12 are distributed and contained in the antiviral agent-containing layer 10 from the surface to a depth of a predetermined thickness is referred to as the "surface vicinity where the antiviral agent-containing layer 10 is exposed."

Therefore, the thickness range of the "surface vicinity" may be appropriately designed depending on the type of antiviral agent 12 used, the method for forming or manufacturing the antiviral agent-containing layer 10 in the antiviral adhesive sheet 100, the application of the antiviral adhesive sheet, the durability of the antiviral agent-containing layer 10 against friction, etc. A typical thickness of the surface vicinity of the antiviral agent-containing layer 10 is preferably in the range of 1 μm or more and 5000 μm or less (however, not exceeding the thickness of the antiviral agent-containing layer 10), and more preferably 3 μm or more and 100 μm or less for normal applications, required durability, and the method for forming or manufacturing the antiviral agent-containing layer.

1(a) to 1(c), an antiviral adhesive sheet 100 in which the antiviral agent-containing layer 10 is a single layer can be produced, for example, by the following methods (A1) and (A2). When an organic antiviral agent is used, method (A2) is preferred in order to reduce the influence of heat and other effects during molding and to make it easier to maintain the function of the antiviral agent.
(A1) A composition containing a binder resin 11 and an antiviral agent 12 is molded by melt extrusion, injection molding, or the like.
(A2) After producing a laminate by forming antiviral agent-containing layer 10 on a substrate having releasability, the substrate having releasability is peeled off from the laminate.

In the antiviral adhesive sheet 100 in FIGS. 2( a ) and ( b ), the antiviral agent-containing layer 10 ′ is in the form of a laminate having a single layer of the antiviral agent-containing layer 10 on the substrate 20 .
The antiviral agent-containing layer 10' in Fig. 2(a) has a single layer of the antiviral agent-containing layer 10 over the entire surface of one side of the substrate 20. The antiviral agent-containing layer 10' in Fig. 2(b) has a single layer of the antiviral agent-containing layer 10 in a partial region of one side of the substrate 20 (the + side in the Z-axis direction in the figure).
As shown in FIGS. 2( a) and 2(b), the antiviral-agent-containing layer 10 monolayer constituting the antiviral-agent-containing layer 10′ may be formed over the entire surface of the substrate 20, or may be formed only on a part of the substrate 20.

2(a) and 2(b), the antiviral-agent-containing layer 10' having the substrate 20 and the single layer of the antiviral-agent-containing layer 10 can be produced by, for example, the following techniques (B1) to (B4). When an organic antiviral agent is used, the technique (B1) or (B4) is preferred in order to make the antiviral-agent-containing layer 10 less susceptible to the effects of heat during lamination and to make it easier to maintain the function of the antiviral agent.
(B1) A composition containing a binder resin 11 and an antiviral agent 12 is applied onto a substrate 20 to form an antiviral agent-containing layer 10 as a coating film, or a sheet formed from the composition is laminated (bonded) onto the substrate 20, with an adhesive layer interposed therebetween as necessary.
(B2) A composition containing binder resin 11 and antiviral agent 12 is melt-extruded onto substrate 20 to form antiviral agent-containing layer 10.
(B3) The substrate 20 and the antiviral agent-containing layer 10 are heated and fused together.
(B4) A laminate is produced by forming an antiviral agent-containing layer 10 on a substrate having releasability. After the surface of the laminate on which the antiviral agent-containing layer 10 is formed is adhered to a substrate 20, the substrate having releasability is peeled off.

The antiviral agent-containing layer 10′ in the antiviral adhesive sheet 100 having the substrate 20 and the antiviral agent-containing layer 10 as shown in FIGS. 2( a) and 2(b) may have other layers, such as an adhesive layer 30 and a second substrate 40, between the substrate 20 and the single layer of the antiviral agent-containing layer 10.
The antiviral agent-containing layer 10" in Fig. 3(a) has an adhesive layer 30 between the substrate 20 and the single layer of the antiviral agent-containing layer 10. The antiviral agent-containing layer 10" in Fig. 3(b) has a second substrate 40 between the substrate 20 and the single layer of the antiviral agent-containing layer 10. The antiviral agent-containing layer 10" in Fig. 3(c) has an adhesive layer 30 and a second substrate 40 between the substrate 20 and the single layer of the antiviral agent-containing layer 10.

3(a) to 3(c) can be produced by, for example, the following techniques (C1) to (C5). When an organic antiviral agent is used, technique (C1), (C2) or (C5) is preferred in order to make it easier to maintain the function of the antiviral agent.
(C1) A single layer of the antiviral agent-containing layer 10 and a substrate 20 are bonded together via an adhesive layer 30.
(C2) The surface of the laminate having a single layer of the antiviral agent-containing layer 10 on the second substrate 40 is bonded to the substrate 20 via the adhesive layer 30.
(C3) The surface of the laminate having a single layer of the antiviral agent-containing layer 10 on the second substrate 40 on the side of the second substrate 40 is heated and welded to the substrate 20.
(C4) A laminate having a single layer of antiviral agent-containing layer 10 on second substrate 40 is placed in a mold. A resin that constitutes substrate 20 and has been made fluid by heating and melting or dissolving in a solvent is poured into the mold, and the fluid resin is solidified by cooling or solvent drying to form the resin into the shape of the mold to form substrate 20, thereby forming substrate 20 on the single layer of antiviral agent-containing layer 10 and the second substrate 40 side of the laminate.
(C5) A laminate having a single layer of antiviral agent-containing layer 10 and adhesive layer 30 on a substrate having releasability, i.e., a transfer sheet, is prepared. The surface of the laminate on the adhesive layer 30 side is brought into close contact with substrate 20, and then the substrate having releasability is peeled off.

That is, specific examples of the layer structure of the antiviral agent-containing layer in the antiviral adhesive sheet 100 include the following (1) to (4). The antiviral adhesive sheet 100 may have other layers not exemplified in the following (1) to (4). Examples of the other layers include a primer layer for improving adhesion, a pattern ink layer for improving design, and a decorative layer made of a metal thin film or the like.
(1) For example, as shown in FIG. 1, a single-layer structure of an antiviral agent-containing layer 10.
(2) For example, as shown in FIG. 2, a configuration having a single antiviral agent-containing layer 10 on a substrate 20.
(3) For example, as shown in FIG. 3( a ), a configuration having an adhesive layer and one single antiviral agent-containing layer on a substrate.
(4) For example, as shown in FIG. 3( c ), a configuration having an adhesive layer 30, a second substrate 40, and a single layer of an antiviral agent-containing layer 10 on a substrate 20.

<Layer Containing Antiviral Agent (Also Referred to as Antiviral Agent-Containing Layer)>
The antiviral agent-containing layer 10 is required to contain an antiviral agent 12. The antiviral agent-containing layer preferably contains an antiviral agent and a binder resin.

Antiviral Agents
Representative examples of the antiviral agent 12 include "antiviral agents comprising a carrier carrying or containing a metal ion,""particles of an imidazole compound,""particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound,""copper-based antiviral agents,""zinc-based antiviral agents," and "radioactive compounds."
Hereinafter, the "antiviral agent comprising a carrier carrying or containing a metal ion" may be referred to as "antiviral agent 1," the "particles of imidazole compound" may be referred to as "antiviral agent 2," the "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound" may be referred to as "antiviral agent 3," the "copper-based antiviral agent" may be referred to as "antiviral agent 4," the "zinc-based antiviral agent" may be referred to as "antiviral agent 5," and the "radioactive compound" may be referred to as "antiviral agent 6."

From the viewpoint of enhancing antiviral properties, it is preferable that the antiviral agent is present in at least a portion of the area near the surface where the antiviral agent-containing layer is exposed. The above configuration can be easily achieved by increasing the content of the antiviral agent or adjusting the specific gravity of the antiviral agent and the binder resin.

Even if the antiviral agent is embedded in the antiviral agent-containing layer, it can exhibit antiviral properties due to the action described below.
For example, antiviral properties can be exhibited by the presence of a substance having antiviral properties on or near the surface of the antiviral agent-containing layer, such as when atoms, ions, compound molecules, etc. having antiviral properties, such as silver ions, are liberated from the antiviral agent, or when the antiviral agent itself bleeds from the inside of the antiviral agent-containing layer 10 to the surface. In addition, when the antiviral agent is a radioactive compound, virus-killing radiation, such as α-rays or β-rays, is radiated to the surface of the antiviral agent-containing layer, so that the antiviral properties can be exhibited.
Alternatively, there may be cases where the virus penetrates (or invades) from the surface of the antiviral agent-containing layer 10 to the interior near the surface through gaps at the interface between the antiviral agent 12 and the binder resin 11, cracks in the antiviral agent-containing layer 10 itself, fine voids such as a porous structure, and comes into contact with the antiviral agent 12 inside the antiviral agent-containing layer 10. In such cases, the antiviral agent 12 inside the antiviral agent-containing layer 10 may exhibit sufficient antiviral properties.

-Antiviral agent 1-
The antiviral agent 1 is an antiviral agent in which a carrier carries or contains a metal ion.
The metal ion of the antiviral agent 1 is preferably either silver or zinc, and more preferably contains both silver and zinc in order to inhibit discoloration and reduce costs.
Silver has better antiviral properties than zinc, but it is expensive and easily discolors due to oxidation. Zinc can prevent silver from discoloring due to oxidation. Therefore, by including both silver and zinc, discoloration can be prevented and costs can be reduced.

As a carrier for the antiviral agent 1, inorganic compounds such as zeolite, apatite, glass, molybdenum, zirconium phosphate, and titanium phosphate are preferred, and among these, porous inorganic compounds are preferred.

Zeolites are aluminosilicates of alkali metals or alkaline earth metals, and both natural and synthetic zeolites can be used. Zeolites are also classified according to their crystal structure into A-type, faujasite type (X-type, Y-type), mordenite type, clinoptilolite type, etc., and any of these can be used.

Apatite is a general term for minerals having a composition represented by the following general formula.
M ₁₀ (ZO ₄ ) ₃ X ₂
In the above formula, M represents Ca, Ba, Mg, Na, K, Fe, Al, etc., Z represents P, S, Si, As, etc., and X represents F, Cl, O, _OH , etc. Representative examples that fall into the above formula include fluorapatite " _Ca10 ( _PO4 ) _6F2 " and hydroxyapatite " _Ca10 ( _PO4 ) ₆ (OH) ₂ ".

Examples of glass include soda glass, borosilicate glass, lead glass, aluminosilicate glass, borate glass, and phosphate glass.

As a method for supporting or containing metal ions in a carrier, a known method may be appropriately selected taking into consideration the form and processing conditions of the antiviral agent-containing layer, the required level of antiviral activity, etc. Here, "containing metal ions" means that metal ions or a substance capable of generating metal ions is held in a carrier in some form. In addition, "substance capable of generating metal ions" means a substance that generates metal ions due to an external factor or a factor over time, such as a substance that generates metal ions by dissolving in water, etc.
Specific examples of the supported or inclusive form include a method of supporting by physical adsorption or chemical adsorption; a method of supporting by an ion exchange reaction; a method of supporting by a binder; a method of inclusion by implanting a silver compound into a support; a method of supporting or inclusion by forming a thin layer of a silver compound on the surface of a support by a thin film formation method such as vapor deposition, dissolution-precipitation reaction, or sputtering; and a method of melting a simple substance such as glass and a metal at high temperature and kneading them.

The antiviral agent 1 is preferably in particulate form.
The shape of the particles of the antiviral agent 1 is not particularly limited, and may be, for example, a sphere, an ellipsoid, a polyhedron, or a scale shape.

The average particle size of the antiviral agent 1 is preferably from 0.1 to 10.0 μm, more preferably from 0.5 to 5.0 μm, and even more preferably from 1.0 to 4.0 μm.
By setting the average particle size to 0.1 µm or more, it becomes easier to obtain stability of the ink containing the antiviral agent 1. Furthermore, by setting the average particle size to 10.0 µm or less, it becomes easier to suppress poor appearance, deterioration in scratch resistance and stain resistance, and whitening of the coating film, and further, it becomes easier to suppress wear of the members of the coating device (such as a coating roll and a doctor blade).

When the average particle size of the antiviral agent 1 is defined as D1 and the thickness of the antiviral agent-containing layer is defined as T, D1/T is preferably 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less.
By making D1/T 1.0 or less, it is possible to easily suppress the decrease in stain resistance and whitening of the coating film, and further to easily suppress the wear of the members of the coating device (coating roll, doctor blade, etc.).

In this specification, the average particle size refers to the mass average value d50 measured in particle size distribution measurement using the laser light diffraction method.

The amount of metal ions in the antiviral agent 1 is preferably 0.1 to 30.0 parts by mass, more preferably 0.5 to 25.0 parts by mass, and even more preferably 1.0 to 20.0 parts by mass, relative to 100 parts by mass of the carrier. Here, the "amount of metal ions" refers to both the supported metal ions and the contained metal ions.
By setting the amount of metal ions to 0.1 parts by mass or more, it is possible to easily improve antiviral properties, and by setting the amount of metal ions to 30.0 parts by mass or less, it is possible to easily suppress discoloration due to light.

The content of the antiviral agent 1 is preferably 0.1 to 50.0 parts by mass, more preferably 0.5 to 17.0 parts by mass, and even more preferably 1.0 to 15.0 parts by mass, relative to 100 parts by mass of the binder resin.
By setting the content of antiviral agent 1 to 0.1 parts by mass or more, it is possible to easily achieve good antiviral properties.
By setting the content of the antiviral agent 1 to 50.0 parts by mass or less, discoloration due to light can be easily suppressed. In addition, by setting the content of the antiviral agent 1 to 50.0 parts by mass or less, deterioration of coating film properties such as coating film strength and scratch resistance can be suppressed. Furthermore, by setting the content of the antiviral agent 1 to 50.0 parts by mass or less, deterioration of contamination resistance and whitening of the coating film can be easily suppressed, and further, wear of coating device members (coating roll, doctor blade, etc.) can be easily suppressed.
When the binder resin is a cured product of a curable resin composition, the content of the antiviral agent 1 is preferably set to be somewhat higher within the above range.

-Antiviral Agent 2-
Antiviral agent 2 is particles of an imidazole compound.
Usually, the imidazole compound is dissolved in the ink containing the imidazole compound. The reason for this is to diffuse the imidazole compound uniformly in any layer, so that the effect of the imidazole compound is exerted throughout the layer. Therefore, when the imidazole compound is used in a normal manner, the imidazole compound does not exist in the form of particles in the antiviral agent-containing layer. That is, the present embodiment is characterized in that the imidazole compound maintains the form of particles.

An imidazole compound is a compound that contains an imidazole skeleton as a structural unit of the molecule. In this embodiment, various imidazole compounds that maintain the particle shape in the antiviral agent-containing layer can be used. As such an imidazole compound, one that is difficult to dissolve in water and organic solvents is preferable, and examples thereof include methyl benzimidazol-2-ylcarbamate (also known as carbendazim) and polymerized imidazole compounds.
However, care should be taken because even methyl benzimidazol-2-yl carbamate (also known as carbendazim) and polymerized imidazole compounds may dissolve in certain solvents. For example, it is preferable to use methyl ethyl ketone, ethyl acetate, etc. as a solvent for methyl benzimidazol-2-yl carbamate (also known as carbendazim).

The shape of the antiviral agent 2 is not particularly limited, and examples include a sphere, an ellipsoid, a polyhedron, a scale shape, etc.

The average particle size of the antiviral agent 2 is preferably from 0.1 to 10.0 μm, more preferably from 0.2 to 8.0 μm, and even more preferably from 0.3 to 7.0 μm.
By setting the average particle size to 0.1 µm or more, it becomes easier to obtain stability of the ink containing the antiviral agent 2. Furthermore, by setting the average particle size to 10.0 µm or less, it becomes easier to suppress poor appearance, deterioration of scratch resistance and stain resistance, and whitening of the coating film.

When the average particle size of the antiviral agent 2 is defined as D2 and the thickness of the antiviral agent-containing layer is defined as T, D2/T is preferably 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less.
By making D2/T 1.0 or less, it is possible to easily suppress poor appearance, deterioration in scratch resistance and stain resistance, and whitening of the coating film.
The lower limit of D2/T is not particularly limited, but is usually 0.01 or more, and preferably 0.05 or more.

The content of the antiviral agent 2 is preferably 0.5 to 20.0 parts by mass, more preferably 1.0 to 13.0 parts by mass, and even more preferably 3.0 to 10.0 parts by mass, relative to 100 parts by mass of the binder resin.
By setting the content of the antiviral agent 2 to 0.5 parts by mass or more, it is possible to easily achieve good antiviral properties.
By setting the content of the antiviral agent 2 to 20.0 parts by mass or less, it is possible to suppress a decrease in the coating film physical properties such as the coating film strength and scratch resistance. Furthermore, by setting the content of the antiviral agent 2 to 20.0 parts by mass or less, it is possible to easily suppress a decrease in contamination resistance and whitening of the coating film.

--Antiviral Agent 3--
The antiviral agent 3 is a particle containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound.

In this specification, "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound" may be "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound", or may be "mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound", or may be a combination of these.

The antiviral agent 3 contains a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound. The components of the styrene polymer derivative compound and the unsaturated carboxylic acid derivative compound preferably have at least one structure selected from the group consisting of styrene, sodium sulfonate, acrylic acid, maleic acid, and fumaric acid, and more preferably have both at least one structure of styrene and sodium sulfonate, and at least one structure selected from the group consisting of acrylic acid, maleic acid, and fumaric acid.

The content ratio of the styrene polymer derivative compound and the unsaturated carboxylic acid derivative compound in the antiviral agent 3 is not limited, but the mass ratio is preferably 30:70 to 70:30, and more preferably 40:60 to 60:40.
When the antiviral agent 3 is a mixture of particles (particles A) containing a styrene polymer derivative compound and particles (particles B) containing an unsaturated carboxylic acid derivative compound, the mass ratio of particles A to particles B is preferably 30:70 to 70:30, and more preferably 40:60 to 60:40.

The reason why antiviral agent 3 exhibits antiviral activity is thought to be as follows, although it is not limited to the mechanism speculated below.
Influenza viruses invade host cells by binding to sugar chain receptors (the sugar chain ends in neuraminic acid) on the surface of the host cells, but since the copolymer containing styrene sulfonate has an ionic group similar to that of neuraminic acid, it is believed that it binds to the virus instead of the host cell, captures the virus, and prevents the virus from binding to the host cell receptor, thereby exerting an antiviral effect. In addition, the unsaturated carboxylic acid derivative compound generates a hydroxyl group (OH-) when it comes into contact with moisture, and the hydroxyl group is believed to have an antiviral effect.

The shape of the antiviral agent 3 is not particularly limited, and examples include a sphere, an ellipsoid, a polyhedron, a scale shape, etc.

The average particle size of the antiviral agent 3 is preferably 0.1 to 10.0 μm, more preferably 0.2 to 8.0 μm, and even more preferably 0.5 to 7.0 μm.
By setting the average particle size to 0.1 µm or more, it becomes easier to obtain stability of the ink containing the antiviral agent 3. Furthermore, by setting the average particle size to 10.0 µm or less, it becomes easier to suppress poor appearance, deterioration of scratch resistance and stain resistance, and whitening of the coating film.

When the average particle size of the antiviral agent 3 is defined as D3 and the thickness of the antiviral agent-containing layer is defined as T, D3/T is preferably 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less.
By making D3/T 1.0 or less, it is possible to easily suppress poor appearance, deterioration in scratch resistance and stain resistance, and whitening of the coating film.
The lower limit of D3/T is not particularly limited, but is usually 0.01 or more, and preferably 0.05 or more.

The content of the antiviral agent 3 is preferably 0.5 to 20.0 parts by mass, more preferably 0.5 to 19.0 parts by mass, even more preferably 1.0 to 17.0 parts by mass, and still more preferably 1.5 to 15.0 parts by mass relative to 100 parts by mass of the binder resin.
By setting the content of the antiviral agent 3 to 0.5 parts by mass or more, it is possible to easily achieve good antiviral properties.
By setting the content of the antiviral agent 3 to 20.0 parts by mass or less, it is possible to suppress a decrease in the coating film physical properties such as the coating film strength and scratch resistance. Furthermore, by setting the content of the antiviral agent 3 to 20.0 parts by mass or less, it is possible to easily suppress a decrease in contamination resistance and whitening of the coating film.

-Antiviral agents 4, 5-
Antiviral agent 4 is a copper-based antiviral agent, and antiviral agent 5 is a zinc-based antiviral agent.
Examples of copper-based antiviral agents include cuprous oxide particles described in Japanese Patent No. 6145758 and copper iodide particles described in WO2010/026730.
Examples of zinc-based antiviral agents include the zinc-based inorganic additives described in Japanese Patent No. 6229429.

-Antiviral Agent 6-
Antiviral agent 6 is a radioactive compound.

To prevent adverse health effects from radiation, radioactive compounds that radiate either alpha rays or beta rays, or both, which have a relatively small flight distance in air or a vacuum and a relatively small penetration rate through various substances, are preferred. In addition, it is preferable for the radioactive compound to radiate alpha rays and/or beta rays with sufficient energy (quantum) to kill viruses, and to radiate small amounts of radiation such as gamma rays, which have a high material penetration rate.

Radioactive compounds that emit alpha rays include ²⁴¹ Am, ²⁴³ Am, ²²⁶ Ra, ²³² Th, etc. Radioactive compounds that emit beta rays include ¹⁴⁷ Pm, ²¹⁰ Po, ⁹⁰ Sr, ⁹⁰ Y, etc.

<Binder resin>
Examples of the binder resin 11 include a thermoplastic resin and a cured product of a curable resin composition. The thermoplastic resin and the cured product of a curable resin composition may be mixed.

Examples of thermoplastic resins include olefin resins such as polyethylene, polypropylene, polymethylpentene, ionomers, and various olefin-based thermoplastic elastomers; vinyl chloride resins such as polyvinyl chloride, polyvinylidene chloride, and vinyl chloride-vinyl acetate copolymers; polyester resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, ethylene glycol-terephthalic acid-isophthalic acid copolymers, and polyester-based thermoplastic elastomers; acrylic resins such as polymethyl (meth)acrylate, polyethyl (meth)acrylate, polybutyl (meth)acrylate, and methyl (meth)acrylate-butyl (meth)acrylate copolymers; polyamide resins such as nylon 6 or nylon 66; cellulose resins such as cellulose triacetate, cellophane, and celluloid; styrene resins such as polystyrene, acrylonitrile-styrene copolymer, and acrylonitrile-butadiene-styrene copolymer (ABS); polyvinyl alcohol; ethylene-vinyl acetate copolymer; ethylene-vinyl alcohol copolymer; polycarbonate resin; urethane resin; polyarylate resin; polyimide resin; and the like. Of these, acrylic resins are preferred.

Examples of the cured product of the curable resin composition include a cured product of a heat-curable resin composition or a cured product of an ionizing radiation-curable resin composition, and among these, a cured product of an ionizing radiation-curable resin composition is preferred from the viewpoints of scratch resistance and production efficiency.

The thermosetting resin composition is a composition that contains at least a thermosetting resin, and is a resin composition that is cured by heating.
Examples of the thermosetting resin include acrylic resin, urethane resin, phenol resin, urea melamine resin, epoxy resin, unsaturated polyester resin, silicone resin, etc. In addition to these thermosetting resins, a curing agent, a curing catalyst, etc. are added to the thermosetting resin composition as necessary.

Representative examples of ionizing radiation curable resin compositions include electron beam curable resin compositions and ultraviolet ray curable resin compositions. Among these, electron beam curable resin compositions are preferred from the viewpoints of having less odor and being less prone to coloration because a polymerization initiator is not required. In addition, when the antiviral agent-containing layer contains an ultraviolet ray absorber described below, electron beam curable resin compositions are preferred in that they tend to increase the crosslink density of the antiviral agent-containing layer and tend to improve scratch resistance and contamination resistance.

The ionizing radiation curable resin composition is a composition containing a compound having an ionizing radiation curable functional group (hereinafter also referred to as an "ionizing radiation curable compound").
The ionizing radiation-curable functional group is a group that is crosslinked and cured by irradiation with ionizing radiation, and preferred examples thereof include functional groups having an ethylenic double bond such as a (meth)acryloyl group, a vinyl group, an allyl group, etc. Further examples of the ionizing radiation-curable functional group include an epoxy group and an oxetanyl group.
In this specification, the term "(meth)acryloyl group" refers to an acryloyl group or a methacryloyl group, and the term "(meth)acrylate" refers to an acrylate or a methacrylate.
In addition, ionizing radiation refers to electromagnetic waves or charged particle beams that have an energy quantum capable of polymerizing or crosslinking molecules. Usually, ultraviolet rays (UV) or electron beams (EB) are used, but other examples include electromagnetic waves such as X-rays and gamma rays, and charged particle beams such as alpha rays and ion beams.
Specifically, the ionizing radiation curable compound can be appropriately selected from polymerizable monomers and polymerizable oligomers (sometimes referred to as "polymerizable prepolymers") that have been conventionally used as ionizing radiation curable resins.

The ionizing radiation curable compound is preferably a compound having two or more ethylenically unsaturated bond groups, and more preferably a polyfunctional (meth)acrylate compound having two or more ethylenically unsaturated bond groups. As the polyfunctional (meth)acrylate compound, either a monomer or an oligomer can be used.

Among the polyfunctional (meth)acrylate compounds, examples of bifunctional (meth)acrylate monomers include ethylene glycol di(meth)acrylate, bisphenol A tetraethoxydiacrylate, bisphenol A tetrapropoxydiacrylate, and 1,6-hexanediol diacrylate.
Examples of trifunctional or higher (meth)acrylate monomers include trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, pentaerythritol tetra(meth)acrylate, dipentaerythritol hexa(meth)acrylate, dipentaerythritol tetra(meth)acrylate, and isocyanuric acid-modified tri(meth)acrylate.
Examples of the polyfunctional (meth)acrylate oligomer include acrylate polymers such as urethane (meth)acrylate, epoxy (meth)acrylate, polyester (meth)acrylate, and polyether (meth)acrylate.

Urethane (meth)acrylates can be obtained, for example, by reacting polyhydric alcohols and organic diisocyanates with hydroxy (meth)acrylates.

Preferred epoxy (meth)acrylates are (meth)acrylates obtained by reacting trifunctional or higher aromatic epoxy resins, alicyclic epoxy resins, aliphatic epoxy resins, etc. with (meth)acrylic acid, (meth)acrylates obtained by reacting difunctional or higher aromatic epoxy resins, alicyclic epoxy resins, aliphatic epoxy resins, etc. with polybasic acids and (meth)acrylic acid, and (meth)acrylates obtained by reacting difunctional or higher aromatic epoxy resins, alicyclic epoxy resins, aliphatic epoxy resins, etc. with phenols and (meth)acrylic acid.

The above ionizing radiation curable resins can be used alone or in combination of two or more.

When the ionizing radiation curable compound is an ultraviolet ray curable compound, the ionizing radiation curable resin composition preferably contains additives such as a photopolymerization initiator and a photopolymerization accelerator.
The photopolymerization initiator may be one or more selected from acetophenone, benzophenone, α-hydroxyalkylphenone, Michler's ketone, benzoin, benzyl dimethyl ketal, benzoyl benzoate, α-acyloxime ester, thioxanthones, and the like.
The photopolymerization accelerator can reduce polymerization inhibition caused by air during curing and increase the curing speed, and examples of the accelerator include one or more types selected from p-dimethylaminobenzoic acid isoamyl ester, p-dimethylaminobenzoic acid ethyl ester, and the like.

Additives
The antiviral agent-containing layer may contain additives such as an antioxidant, a light stabilizer, an ultraviolet absorbing agent, a matting agent, and a colorant.

Thickness
The thickness of the single layer portion of the antiviral agent-containing layer 10 can be, for example, from 1.0 μm to 10,000 μm (1 cm) from the viewpoint of a balance between processing characteristics and scratch resistance.
When the antiviral adhesive sheet 100 is constructed from a single layer of an antiviral agent-containing layer, the thickness of the antiviral agent-containing layer is preferably made thicker. In the case of a single layer, the thickness of the antiviral agent-containing layer is preferably 1.0 μm or more and 10,000 μm or less, and more preferably 10 μm or more and 5,000 μm or less.
On the other hand, when the antiviral agent-containing layer has a substrate, the substrate is responsible for self-supporting properties and durability against external forces, the antiviral effect is saturated at a certain thickness, and the processability decreases as the thickness of the monolayer portion of the antiviral agent-containing layer increases, taking into consideration the above factors. When the antiviral agent-containing layer has a substrate, the thickness of the monolayer portion of the antiviral agent-containing layer is preferably a thin film, from the viewpoint of the balance between processability and scratch resistance. When the antiviral agent-containing layer has a substrate, the thickness of the monolayer portion of the antiviral agent-containing layer is preferably 1.5 μm or more and 30 μm or less, more preferably 2 μm or more and 20 μm or less, and even more preferably 3 μm or more and 15 μm or less.

From the viewpoint of ease of handling, the antiviral agent-containing layer is preferably configured to have a single antiviral agent-containing layer on a substrate. In addition, an antiviral agent-containing layer having a single antiviral agent-containing layer on a substrate may further have other layers such as an adhesive layer and a decorative layer.

<Suction cup adhesive layer>
A suction cup adhesive layer 50 is laminated on one surface of the antiviral agent-containing layers 10, 10', and 10" opposite the surface that will be exposed as the outermost surface after the antiviral adhesive sheet 100 is adhered to the surface of the adherend. That is, the antiviral adhesive sheet 100 is adhered to the surface of the adherend via the suction cup adhesive layer 50.
Unlike ordinary adhesives, the suction cup adhesive layer 50 instantly exerts its adhesive strength by simply contacting and applying pressure, and therefore does not require time to exert its adhesive strength, treatment such as drying, or energy supply such as heating or ionizing radiation irradiation. Therefore, the antiviral adhesive sheet 100 can be easily adhered to the surface of the adherend, and the surface can be given antiviral properties. In addition, by setting the adhesive strength of the suction cup adhesive layer 50 to a low level, when an adhesion defect such as misalignment, wrinkles, or loosening occurs during adhesion, the antiviral adhesive sheet 100 can be peeled off once, and then the peeled antiviral adhesive sheet 100 can be reattached (re-applied) after the defect is eliminated.

The suction cup adhesive layer 50 has a plurality of recessed shapes 50a that open on both sides. The suction cup adhesive layer 50 also has elasticity, and each of the plurality of recessed shapes 50a acts as a minute suction cup, so that it can exert adhesive force (adsorption force) on a variety of adherends.

The suction cup adhesive layer 50 is formed, for example, using a liquid resin composition (acrylic emulsion) disclosed in JP 2017-36404 A (hereinafter referred to as Patent Document 3). In particular, it is preferably made of a one-component curing acrylic resin. A one-component curing type is less likely to have the problems of being difficult to peel off due to the increased adhesive strength caused by the hardening in a heated environment, as is the case with two-component curing types, and of leaving adhesive residue when peeled off. In addition, since acrylic resin does not contain chlorine atoms, it is advantageous from an environmental perspective, as it basically only emits carbon dioxide and water even if it is incinerated at the time of disposal.

The thickness t of the suction cup adhesive layer 50 is preferably 1 μm or more and 500 μm or less. If the thickness falls below the lower limit of the above layer thickness range, it becomes difficult to form a concave shape, or the size of the concave shape becomes too small, resulting in a decrease in adhesive (adsorption) properties. If the thickness exceeds the upper limit of the above layer thickness range, the flexibility of the anti-slip floor decorative sheet decreases, resulting in poor workability.
Furthermore, in order to provide the recesses 50a evenly on both sides of the suction cup adhesive layer 50, it is desirable that the thickness t of the suction cup adhesive layer 50 be in the range of 20 μm≦t≦40 μm. This point will be described later.

The size and density of the concave shape 50a of the suction cup adhesive layer 50 can be adjusted by changing various conditions in the manufacturing process described below. For example, the density of the suction cup adhesive layer 50 can be used as an index representing the degree to which the suction cup adhesive layer 50 contains the concave shape 50a. The density of the suction cup adhesive layer 50 is not particularly limited, but can be, for example, 0.1 g/ ^cm3 or more and 0.6 g/ ^cm3 or less. The size of the concave shape 50a is not particularly limited, but can be, for example, 1 μm or more and 300 μm or less.

When attaching the antiviral adhesive sheet 100 to an adherend, the suction cup adhesive layer 50 is brought into contact with the adherend and an appropriate amount of pressure is applied, causing the numerous concave shapes 50a present on the exposed surface of the adhesive layer to elastically deform, so that the sheet adheres (sticks) to the adherend in a manner similar to that of a conventional micro suction cup.

That is, the elastic deformation around the concave shape 50a exerts a force on the concave shape 50a to return it to its original shape from the deformed state. This force creates a negative pressure in the sealed space inside the concave shape 50a, causing the concave shape 50a to adhere to the adherend. Although the adsorption force of the concave shape 50a alone is weak, since many concave shapes 50a are formed, the necessary adsorption force can be secured as a whole. In addition, when the suction cup adhesive layer 50 is produced, the amount of the concave shapes 50a contained therein can be adjusted, for example, by adjusting the density as a parameter, so that the adhesive force (adsorption force) of the suction cup adhesive layer 50 can be adjusted.

(Verification experiment on the concave shape 50a of the suction cup adhesive layer 50)
As described above, in the present invention, the concave shapes 50a of the suction cup adhesive layer 50 have a large effect on the adhesive strength. If the concave shapes 50a are not evenly provided on both sides of the suction cup adhesive layer 50, there is a risk that the adhesive strength (adhesive strength) of one side of the adhesive layer will be lowered or increased compared to the other side. Furthermore, by providing the concave shapes 50a evenly on both sides of the suction cup adhesive layer 50, the physical properties of the suction cup adhesive layer 50 will also be uniform, which is also preferable in terms of achieving sufficient adhesive strength on both sides of the suction cup adhesive layer 50 and removability from the adherend.

In order to provide the concave shapes 50a evenly on both sides of the suction cup adhesive layer 50, it is important to manage the application amount (thickness t) of the suction cup adhesive layer 50. Patent Document 3 does not take this into consideration at all, and it is sufficient that micro-suction cups are simply formed. In Patent Document 3, in FIG. 2 of Patent Document 3, which is a cross-sectional photograph of Example 1 formed with a wet film thickness of 800 μm, a fine suction cup structure is formed in the portion shown as the surface having the micro-suction cups, but a structure that appears to be a huge bubble that is incomparable to the previous fine suction cup structure can be confirmed in the portion shown as the surface peeled off from the glass substrate. That is, in Patent Document 3,
In the configuration, micro-suction cups (corresponding to the concave shapes 50a in this embodiment) are formed on one surface of the adhesive layer, but the other surface is substantially free of micro-suction cups (concave shapes 50a).

The present applicant also conducted verification experiments on this point.
As a verification experiment, four types of adhesive layer samples were prepared, and the concave shapes 50a on both sides of each sample were observed by SEM.
Sample 1: Adhesive layer thickness t = 25 μm
Sample 2: Adhesive layer thickness t = 30 μm
Sample 3: Adhesive layer thickness t = 35 μm
Sample 4: Adhesive layer thickness t ≒ 2000 μm
The thickness t of the adhesive layer in the above samples is the thickness t after drying. For Samples 1 to 3, the bubble-containing composition after foaming was applied to the glass surface using a coater, and then dried using a drying oven at 100°C. For Sample 4, the composition was applied dropwise to the glass surface and naturally dried at room temperature. The drying conditions for Sample 4 were changed in order to verify the statement in Patent Document 3 that drying at room temperature is sufficient. For all samples, the density of the adhesive layer after foaming was 0.4 g/ ^cm3 .

It was confirmed that in Samples 1 to 3 in which the thickness t of the adhesive layer was controlled, the fine recesses 50a were evenly formed on both sides.
In contrast, in Sample 4, which had a large film thickness, a large difference in size of the concave shapes 50a was observed between the dry surface and the glass side surface, and the same results as those shown in FIG. 2 of Patent Document 3 were obtained.
Therefore, in order to provide the recesses 50a evenly on both sides of the suction cup adhesive layer 50, it can be determined that the thickness t of the suction cup adhesive layer 50 is preferably in the range of 20 μm≦t≦40 μm.

In addition, the coating amount of the suction cup adhesive layer 50 is preferably 13 g/ ^m2 or more and 70 g/ ^m2 or less. If it exceeds 70 g/ ^m2 , there is a problem that it takes a long time to dry. If it is heated to shorten the drying time, there is a concern that the substrate having releasability (a layer different from the substrate having releasability depending on the layer structure and the target to which the suction cup adhesive layer is applied) may be adversely affected by shrinkage due to heat. On the other hand, if it is less than 13 g/ ^m2 , there is a problem that the coating liquid is repelled (the coating liquid is not applied) in the coating process, that is, it is difficult to apply the coating liquid uniformly.

Here, in order for the concave shapes 50a to be evenly provided on both sides of the suction cup adhesive layer 50, it is preferable that the following relationship be satisfied.
When the average diameter of each opening of the concave shape 50a opening on the surface facing the antiviral agent-containing layer is denoted as D ^ave ₁ and the average diameter of each opening of the concave shape 50a opening on the surface facing the releasable substrate is denoted as D ^ave ₂ ,
|D ^ave ₁ - ^{D ave} ₂ |/D ^ave ₂ ≦0.5
It is desirable to satisfy the following relationship.
|D ^ave ₁ - ^{D ave} ₂ |/D ^ave ₂ ≦0.25
It is more preferable that the following relationship is satisfied.

By satisfying these relationships, it is possible to reduce the difference in adhesive strength between both sides of the suction cup adhesive layer, and it is also possible to ensure sufficient adhesive strength and good removability from the adherend on both sides of the suction cup adhesive layer 50.
In addition, since it is practically impossible to obtain the average of all openings, the diameters of the three openings, starting from the largest, were measured within an observation range of 1500 μm × 1100 μm, and the average value was calculated.

Here, the openings were measured for Samples 1 to 4, and |D ^ave ₁ -D ^ave ₂ |/D ^ave ₂ was calculated to give Sample 1: 0.04, Sample 2: 0.06, Sample 3: 0.12, and Sample 4: 0.69.

<Base material>
The form of the substrate is not particularly limited, and may be a flat plate such as a film, sheet, or plate.
Although films, sheets, and plates are often referred to as films, sheets, and plates in the order of relatively thinnest thickness, in this specification no distinction is made between these three unless otherwise specified.

Materials constituting the substrate include resins, metals, non-metallic inorganic materials, fibrous materials, and wood-based materials, and can be selected appropriately depending on the application.

The substrate may be a single layer, or may be a laminate of two or more layers made of the above materials. When the substrate is a laminate of two or more layers, it is preferable that two or more layers of different materials are laminated, and the performance properties of the materials of each layer are complemented. Examples of substrates having two or more layers laminated include A to J below. Note that "/" indicates the interface between the layers.
(A) Resin/wood-based material (B) Resin/metal (C) Resin/fibrous material (D) Resin/non-metallic inorganic material (E) Resin 1/Resin 2
(F) Metal/wood-based materials (G) Metal/non-metallic inorganic materials (H) Metal/fibrous materials (I) Metal 1/Metal 2
(J) Non-metallic inorganic materials/fibrous materials

In E above, resin 1 and resin 2 are different resins (for example, resin 1 is olefin resin and resin 2 is acrylic resin). Also, in H above, metal 1 and metal 2 are different metals (for example, metal 1 is copper and metal 2 is chromium).

In addition, when the substrate is a laminate such as those A to J above, the laminate may have a layer (such as an adhesive layer) between each of the constituent layers to strengthen the adhesive strength.

The resins used as the substrate include various synthetic resins or natural resins. As synthetic resins, thermoplastic resins and curable resins can be used.

Examples of the thermoplastic resin include the thermoplastic resins exemplified as the binder resin of the antiviral agent-containing layer.
Examples of the curable resin include the thermosetting resins and ionizing radiation curable resins exemplified as the binder resin of the antiviral agent-containing layer.
Natural resins include natural rubber, rosin, and amber.

Metals that can be used as the substrate include, for example, aluminum or aluminum-containing alloys such as duralumin, iron or iron-containing alloys such as carbon steel and stainless steel, copper or copper-containing alloys such as brass and bronze, gold, silver, chromium, nickel, cobalt, tin, titanium, etc. Metal substrates that have been plated with these metals can also be used.

Non-metallic inorganic materials used as substrates include, for example, non-ceramic ceramic materials such as cement, ALC (lightweight aerated concrete), gypsum, calcium silicate, and wood chip cement; ceramic ceramic materials such as porcelain, earthenware, glass, and enamel; and natural stones such as limestone (including marble), granite, andesite.

Examples of fibrous materials used as the substrate include tissue paper, kraft paper, wood-free paper, Japanese paper, titanium paper, linter paper, parchment paper, glassine paper, backing paper for wallpaper, base paper for paperboard and gypsum board, and other papers, woven or nonwoven fabrics made of fibers such as polyester resin fiber, acrylic resin fiber, protein-based or cellulose-based natural fibers such as silk, cotton, and hemp, glass fiber, and carbon fiber. These papers may further contain resins such as acrylic resin, styrene butadiene rubber, melamine resin, and urethane resin (impregnated with resin after papermaking, or filled in during papermaking) to increase the strength between the fibers of the paper substrate or between other layers and the paper, and to prevent fluffing. Examples of papers to which resin has been added include inter-paper reinforced paper and resin-impregnated paper.
An example of a substrate in which a resin layer is laminated onto a fibrous material layer is wallpaper base material in which a resin layer such as a polyvinyl chloride resin layer, an olefin resin layer, an acrylic resin layer or the like is laminated onto the surface of wallpaper backing paper, which is often used in the building materials field.

Examples of wood-based materials used as substrates include cedar, cypress, pine, oak, lauan, teak, and rubberwood. Examples of the form of the substrate for wood-based materials include veneer, plywood, laminated lumber, particle board, and veneer.

The shape and dimensions of the substrate are not particularly limited and may be appropriately selected depending on the application, desired performance properties and processability.
In the case where the substrate is a flat plate such as a film, sheet, or plate, the thickness is a typical dimension in the design of the article. There is no particular limit to the thickness, but it is generally set to about 10 μm or more and 10 cm or less from the viewpoints of manufacturing and processing suitability, mechanical strength, ease of use and handling, and economic efficiency. In the case of a film or sheet form, a thickness of about 20 μm or more and 500 μm or less is usually selected, and in the case of a plate form, a thickness of about 1 mm or more and 2 cm or less is usually selected.

In order to improve adhesion to other layers constituting the monolayer of the antiviral-agent-containing layer 10, or adhesion between the antiviral adhesive sheet 100 and a member to be laminated thereto, one or both sides of the substrate can be subjected to a surface treatment such as a physical surface treatment such as an oxidation method or a roughening method, or a chemical surface treatment.
Examples of the oxidation method include corona discharge treatment, chromium oxidation treatment, flame treatment, hot air treatment, ozone-ultraviolet treatment, etc., and examples of the roughening method include sandblasting, solvent treatment, etc. Although these surface treatments are appropriately selected depending on the type of substrate, generally, corona discharge treatment is preferably used in terms of the effect of the surface treatment, operability, etc.

<Adhesive layer>
Examples of adhesives constituting the adhesive layer 30 for laminating a single layer of the antiviral agent-containing layer 10 on the substrate 20 include general-purpose adhesives such as moisture-curing adhesives, anaerobic-curing adhesives, dry-curing adhesives, UV-curing adhesives, and heat-sensitive adhesives (e.g., hot-melt adhesives). Examples of the various adhesives mentioned above include urethane-based adhesives, acrylic-based adhesives, epoxy-based adhesives, and rubber-based adhesives, and among these, urethane-based adhesives are preferred in terms of adhesive strength.

Examples of urethane-based adhesives include adhesives that use two-component curing urethane resins that contain various polyol compounds, such as polyether polyols, polyester polyols, and acrylic polyols, and curing agents, such as isocyanate compounds.

The thickness of the adhesive layer is preferably 0.1 μm or more and 60 μm or less, more preferably 1 μm or more and 50 μm or less, and even more preferably 5 μm or more and 40 μm or less.

<Second base material>
The second substrate may be the same as the substrate described above.
The second substrate is often used as a support when forming a monolayer of the antiviral agent-containing layer. For this reason, the second substrate is preferably a resin substrate from the viewpoint of ease of handling. In addition, the thickness of the second substrate is preferably 10 to 300 μm, more preferably 20 to 200 μm, and even more preferably 30 to 150 μm, from the viewpoint of ease of handling.

<Antiviral activity value>
The antiviral pressure-sensitive adhesive sheet 100 of the present embodiment preferably has an antiviral activity value of 2.0 or more as measured by the following method. The following method is a method in accordance with ISO21702.

<Method for measuring antiviral activity value>
0.4 ml of virus liquid is dropped onto a 5 cm square test piece (antiviral treated product and non-treated product) and covered with a 4 cm square film. The test piece is left to stand at 25°C for 24 hours. After standing, the virus on the test piece is washed off and collected, and the virus infectivity is measured. The antiviral activity value is calculated using the following formula (1).
R=Ut-At (1)
R: Antiviral activity value Ut: Average common logarithm of viral infectivity (PFU/cm ² ) of untreated products after standing for 24 hours At: Average common logarithm of viral infectivity (PFU/cm ² ) of antiviral treated products after standing for 24 hours

<HAZE>
In a form in which the antiviral adhesive sheet 100 of the present embodiment has transparency, there are cases where a high haze like cloudy glass is required, and cases where a low haze is required. When a low haze is required, the haze is preferably 30% or less, and more preferably 20% or less. Haze refers to the haze defined in JIS K7136:2000. In order to reduce the haze, it is preferable to reduce the difference in refractive index between the antiviral agent and the binder resin, to reduce the content of the antiviral agent, or to reduce the thickness of the antiviral agent-containing layer.

<Application>
The antiviral adhesive sheet 100 of the present disclosure can be suitably used to impart antiviral properties to the surface of such adherends relatively easily and in a short time, even by non-expert technicians, for example, in the following locations to which antiviral properties should be imparted, such as in various members, products, daily living spaces, workplaces or business activities, medical facilities, etc.
(1) Surfaces of interior parts such as walls, floors, and ceilings of buildings such as homes, offices, stores, hospitals, and clinics.
(2) The surfaces of exterior parts such as exterior walls, roofs, eaves ceilings, door pockets, etc. of buildings such as houses, offices, stores, hospitals, and clinics.
(3) Surfaces of fittings such as windows, window frames, doors, and door frames (interior or exterior parts); surfaces of fitting accessories (handles, etc.); surfaces of fitting jigs.
(4) The surfaces of construction components such as handrails, waist walls, moldings, thresholds, lintels, and top boards.
(5) Surfaces of outdoor (exterior) parts such as pillars and handrails of fences, gates, and clothes drying racks.
(6) Surface materials of furniture such as chests of drawers, desks, chairs, cupboards, kitchen sinks, etc.; surface materials of furniture accessories (handles, etc.); surfaces of furniture fixtures.
(7) Surface materials for the housings of various home appliances such as television receivers, radio receivers, refrigerators, microwave ovens, washing machines, electric fans, air conditioners, etc.; surface materials for accessories of home appliances (handles, switches, touch panels, etc.); surfaces of fixtures for home appliances.
(8) Surface materials of office equipment such as various computing devices such as electronic copiers, facsimiles, printers, and personal computers; surfaces of the housings of various office equipment such as ATM devices at financial institutions such as banks and post offices; surfaces of accessories for various office equipment (keyboards, touch panels, etc.); surfaces of tools for various office equipment.
(9) Surfaces of the interior or exterior of vehicles such as automobiles, railway cars, ships, aircraft, etc. (walls, floors, ceilings, handrails, supports, control panels, levers, handles, steering wheels, and other control equipment).
(10) Partitions in various buildings; shielding plates or curtains to prevent droplet infection of viruses at counters of stores, offices, government offices, etc., accounting settlement locations, etc.; face protection equipment such as protective masks (face guards) and protective glasses (goggles); or the surfaces of these.
(11) Business forms such as receipts; bankbooks; cards such as cash cards, credit cards, and point cards of financial institutions; or the surfaces of any of these.
(12) Glass, resin, etc. bottles; metal cans; resin soft packaging materials such as resin retort containers; packaging materials such as various tubes; or the surfaces of these.

Above (6) illustrates an example in which the antiviral adhesive sheet 100 of the present disclosure is applied to a desk as an adherend. In this case, it is preferable to apply the antiviral adhesive sheet 100 to the work surface (horizontal surface) of the desk, and in this case, it is preferable that the antiviral adhesive sheet 100 can be used as a desk mat as is. In an example in which the antiviral adhesive sheet 100 is used as a desk mat, the antiviral agent-containing layer 10 forms the surface of the desk mat when in use.

Reference Signs List 100: Antiviral adhesive sheet 10, 10', 10": Antiviral agent-containing layer 11: Binder resin 12: Antiviral agent 20: Substrate 30: Adhesive layer 40: Second substrate 50: Suction cup adhesive layer 50a: Concave shape

Claims (4)

An antiviral adhesive sheet comprising an antiviral agent-containing layer and a suction cup adhesive layer laminated on one side thereof,
the antiviral agent contained in the antiviral agent-containing layer is a carrier carrying or containing a metal ion,
the average particle size of the antiviral agent is 0.1 to 10.0 μm, and the amount of metal ions in the antiviral agent is 0.1 to 30.0 parts by mass relative to 100 parts by mass of the carrier,
said suction cup adhesive layer has a plurality of concave shapes on both sides, the average value of the diameter of each opening of said concave shapes opening on one side is denoted as D ^ave ₁ , and the average value of the diameter of each opening of said concave shapes opening on the other side of said suction cup adhesive layer is denoted as D ^ave ₂ ,
|D ^ave ₁ - ^{D ave} ₂ |/D ^ave ₂ ≦0.5
An antiviral adhesive sheet that satisfies the above requirements. An antiviral adhesive sheet comprising an antiviral agent-containing layer and a suction cup adhesive layer laminated on one side thereof,
the antiviral agent contained in the antiviral agent-containing layer is a particle containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound,
the average particle size of the antiviral agent is 0.1 to 10.0 μm, and the content of the antiviral agent is 0.5 to 20.0 parts by mass relative to 100 parts by mass of the binder resin,
said suction cup adhesive layer has a plurality of concave shapes on both sides, the average value of the diameter of each opening of said concave shapes opening on one side is denoted as D ^ave ₁ , and the average value of the diameter of each opening of said concave shapes opening on the other side of said suction cup adhesive layer is denoted as D ^ave ₂ ,
|D ^ave ₁ - ^{D ave} ₂ |/D ^ave ₂ ≦0.5
An antiviral adhesive sheet that satisfies the above requirements. 3. The antiviral adhesive sheet according to claim 1, wherein the suction cup adhesive layer is made of a one-component curing acrylic resin. The antiviral adhesive sheet according to any one of claims 1 to 3 , wherein the coating amount of the suction cup adhesive layer is 13 g/ ^m2 or more and 70 g/ ^m2 or less.